Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 6/20 | 0.57 |
| ▸ | SCD | O00767 | 8/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24183660 | 1.00 | ADRA2C (0.57) | ADRA2CSCDHRH3ADRA1AACKR3 | |
| SCHEMBL24183569 | 0.91 | ADRA2C (0.56) | ADRA2CHRH3ADRA1AACKR3 | |
| SCHEMBL29876797 | 0.91 | ADRA2C (0.56) | ADRA2CHRH3ADRA1AACKR3 | |
| SCHEMBL24183593 | 0.91 | ADRA2C (0.56) | ADRA2CHRH3ADRA1AACKR3 | |
| SCHEMBL24183596 | 0.91 | ADRA2C (0.56) | ADRA2CHRH3ADRA1AACKR3 | |
| SCHEMBL24183686 | 0.91 | ADRA2C (0.56) | ADRA2CHRH3ADRA1AACKR3 | |
| SCHEMBL30359073 | 0.90 | ADRA2C (0.55) | ADRA2CHRH3ADRA1AACKR3 | |
| SCHEMBL24183452 | 0.90 | ADRA2C (0.55) | ADRA2CHRH3ADRA1AACKR3 | |
| SCHEMBL24183620 | 0.89 | ADRA2C (0.57) | ADRA2CHRH3ADRA1AACKR3 | |
| SCHEMBL30379971 | 0.89 | ADRA2C (0.57) | ADRA2CHRH3ADRA1AACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| CN-118434414-A | Combinations of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and muscarinic receptor antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA2 | ADRA2C 1/4885SCD 2435/4885HRH3 98/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | ADRA2C 1/4885SCD 687/4885HRH3 115/4885 |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | ADRA2C, ADRB2, ADRB3 | ADRA2C 1/4885SCD 793/4885HRH3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.